Successful treatment of pyoderma gangrenosum with concomitant tofacitinib and infliximab

TY - JOUR

T1 - Successful treatment of pyoderma gangrenosum with concomitant tofacitinib and infliximab

AU - Gregory, Martin H.

AU - Ciorba, Matthew A.

AU - Deepak, Parakkal

AU - Christophi, George P.

N1 - Funding Information: From the Division of Gastroenterology and Hepatology, Washington University School of Medicine, St. Louis, Missouri Conflict of interest: M.C.: speakers bureau or consulting for UCB, AbbVie, Pfizer, and Takeda; grant support from Incyte, AbbVie, and Takeda. P.D.: received consulting fees from Janssen and Pfizer, speaker fees from Abbvie, and a research grant from Takeda. M.H.G., G.C.: Each of these authors reports no disclosures or conflicts of interest relevant to this study. Funding Information: Supported by: No external funding was used for this project.

PY - 2019/6/18

Y1 - 2019/6/18

UR - https://www.scopus.com/pages/publications/85068382245

U2 - 10.1093/ibd/izz015

DO - 10.1093/ibd/izz015

M3 - Letter

C2 - 30753456

AN - SCOPUS:85068382245

SN - 1078-0998

VL - 25

SP - E87-E88

JO - Inflammatory bowel diseases

JF - Inflammatory bowel diseases

IS - 7

ER -